Gender; women (%) 39 ( Objectives: We aimed to recognize young adults with JIA who are socioeconomically passivated and to assess which areas of self-rated health are associated with the emergence of passivity symptoms. Methods: We studied 195 young adults with JIA using questionnaires addressing demographics, health behavior, and physical activity. The HAQ questionnaire was used to assess functional ability, quality of life was assessed with RAND-36, depressive symptoms were assessed with BDI-II, and self-esteem was evaluated by using the Rosenberg scale. Patients were classified as active if they were engaged in studying, working, maternal leave or military service; and as passive, if they were unemployed or on disability pension. Results: 80% of the patients were female, mean age was 23 years, and disease duration was approximately 15 years. Patients in the passive group participated less in leisure time non-physical activities (p =0.033), they felt more disturbed during their leisure time (p =0.010). Leisure time physical activity did not reveal statistically significant differences between the groups. The majority of the patients in the passive group (58%) had only basic education (p<0.001), they visited their doctor more frequently (p=0.019) and they used oral prednisolone more often (p<0.018). Approximately 70% of the patients received disease modifying antirheumatic drugs, and nearly half of the patients were treated with biologicals in both of the groups. Mean disability scores on HAQ were higher in the passive group (p=0.012). Depressive symptoms did not differ between the groups. Selfesteem was lower in the passive group (p=0.002). Results in health related quality of life revealed statistically significant differences between the groups: physical functioning (p=0.049), social functioning (p =0.020), and emotional well-being (p=0.047) were significantly lower in the passive group. Conclusions: Patients being socioeconomically more passive showed higher degrees of disability, reporting lower physical functioning, self-esteem, emotional well-being, and social functioning. Those patients should be recognized earlier and activating interventions should be provided. Background: Chronic relapsing multifocal osteomyelitis (CRMO) is a rare autoinflammatory bone condition presenting primarily in children and adolescents. It characteristically affects the epiphysis and metaphysis of long bones, and presents with bony pain, local swelling and warmth. Objectives: The aim of this study was to collate our tertiary adolescent rheumatology centre's experience of managing patients with CRMO, and establish their longer term outcomes, possible by the fact we have a cohort of patients with CRMO under long-term follow-up. Methods: We carried out a retrospective case note review of all patients who are known to our service with a diagnosis of CRMO, presenting between age 13-20. Results: In total 17 patients were identified as having CRMO, presenting between 1999 and 2015. 10 patients were female, and 7 patients male. The median age of initial symptoms, and age of presentation was 12 years (range1-16 years). Median duration of follow up is 4.75 years (range 1-16.5 years). Since initial diagnosis, 3 patients evolved into a SAPHO (synovitis, acne, pustolosis, hyperostosis, osteitis) phenotype, 3 an ERA (enthesitis related arthritis) phenotype and 2 patients developed oligoarticular juvenile idiopathic arthritis (JIA). 35% of patients have a purely unifocal disease, and 65% have multifocal disease as confirmed by whole body MRI. 70.5% patients had recurrent episodes of inflammation, while 29.5% of patients had only one flare and then reached remission (either clinical or confirmed with MRI). 15 patients had their diagnosis confirmed with biopsy, while 2 did not due to site of disease. Their diagnosis is assumed based on clinic impression, and typical radiographic findings. Sites of disease confirmed in our patients include lower limbs (70% patients), upper limbs (35% patients), clavicle (29.4%), mandible (17.6%) and spine/pelvis (23.5%). All patients were treated with NSAIDs. In terms of treatments used since diagnosis, 76% patients have been on methotrexate (MTX), 47% had one infusion of pamidronate, and 23% required more than one infusion of pamidronate. Other medications include sulfasalazine (SSZ), azathioprine, risedronate and anti-TNFs (adalimumab, etanercept and infliximab). On last clinic review, with or without imaging, 35% of patients continue to have active disease. Currently 29% patients are on MTX alone, 23% patients are on adalimumab and MTX, and 35% are only maintained on NSAIDS. Of those without active disease 5 patients (45%) are not on any DMARD or biologic therapy. Conclusions: We present here our experience of managing adolescent patients with CRMO. The perceived wisdom is that CRMO is a self-limiting disease which eventually goes into remission. However our centre's experience is that nearly 50% of our patients have a disease which evolves into another systemic autoimmune disease, mainly SAPHO, polyarticlar or enthesitis related JIA. Previous case series have suggested only 0-30% of patients' disease evolves. This may be a reflection of our older cohort of patients, who are only referred to our service with ongoing disease. The majority of patients have a recurrent and multifocal course of disease. The most common site of disease was in the lower limbs. All patients were treated with NSAIDS, and a combination of DMARDS, bisphosphonates and biologic agents have been used, which has resulted in remission of disease in the majority of patients. Disclosure of Interest: None declared DOI: 10.1136/annrheumdis-2017-eular.5188 
